Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer (Q42032055)

From Wikidata

Jump to navigation Jump to search

scientific article published on 3 August 2012

Language	Label	Description	Also known as
English	Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer	scientific article published on 3 August 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

phase III clinical trial

0 references

prostate cancer

1 reference

based on heuristic

inferred from title

Philip W. Kantoff

3

object named as

Philip W Kantoff

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

author name string

Nadeem A Sheikh

1

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

Daniel Petrylak

2

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

Corazon Dela Rosa

4

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

Frances P Stewart

5

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

Ling-Yu Kuan

6

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

James B Whitmore

7

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

James B Trager

8

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

Christian H Poehlein

9

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

Mark W Frohlich

10

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

David L Urdal

11

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

publication date

3 August 2012

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

62

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

1

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

137-147

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

Integrated Safety Data From 4 Randomized, Double-Blind, Controlled Trials of Autologous Cellular Immunotherapy With Sipuleucel-T in Patients With Prostate Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541926

5 June 2018

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541926

5 June 2018

Prostate cancer as a model for tumour immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541926

5 June 2018

DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541926

5 June 2018

Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8 and CD4 T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541926

5 June 2018

Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541926

5 June 2018

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541926

5 June 2018

Noninvasive in vivo imaging of CD4 cells in simian-human immunodeficiency virus (SHIV)-infected nonhuman primates.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541926

5 June 2018

Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541926

5 June 2018

T cell homeostasis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541926

5 June 2018

Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541926

5 June 2018

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541926

5 June 2018

Molecular signatures distinguish human central memory from effector memory CD8 T cell subsets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541926

5 June 2018

Functions of granulocyte-macrophage colony-stimulating factor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541926

5 June 2018

Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541926

5 June 2018

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541926

5 June 2018

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541926

5 June 2018

Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541926

5 June 2018

Number and distribution of lymphocytes in man. A critical analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541926

5 June 2018

A novel hybridoma antibody (PASE/4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541926

5 June 2018

Interleukin-1, immune activation pathways, and different mechanisms in osteoarthritis and rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541926

5 June 2018

Lymphocyte specificity to protein antigens. I. Characterization of the antigen-induced in vitro T cell-dependent proliferative response with lymph node cells from primed mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541926

5 June 2018

A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541926

17 August 2018

Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541926

17 August 2018

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3541926

17 August 2018

Antigen Specific T-Cell Responses Against Tumor Antigens are Controlled by Regulatory T Cells in Patients With Prostate Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22865266

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin 1: a common endogenous mediator of inflammation and the local Shwartzman reaction

1 reference

https://pubmed.ncbi.nlm.nih.gov/22865266

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22865266

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22865266

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores

1 reference

https://pubmed.ncbi.nlm.nih.gov/22865266

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses

1 reference

https://pubmed.ncbi.nlm.nih.gov/22865266

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD54 is a surrogate marker of antigen presenting cell activation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22865266

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00262-012-1317-2

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42032055&oldid=2204969012"